Development and Evaluation of Matrix Type Transdermal Patches of Torasemide

Ashish Kumar*, Kapil Kumar

Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India

ABSTRACT

TDDS manufacture has numerous benefits over other routes like oral delivery. It avoids limitations linked with g.i.t. absorption, enzyme effect, interaction with drug and food. This route is suitable when patient is suffering from vomiting and diarrhea. Torasemide is a loop diuretic; it comes under category of sulfonyl urea. It is prescribed in the treatment of edema, CHF, and hypertension. Whenever it is used by oral route, it is associated with many side effects like vomiting, nausea, anorexia, and increased appetite. All transdermal patches were transparent and free from any particle. Release profile of twelve batches of Torasemide was done by the means of Franz cell for 7 hrs. Maximum release was shown by MTP6 (71.28±0.19) and least in formulations of batch code MTP7 (24.47±0.04). In-vitro release data were plotted in 2 different models i.e. first and Korsemeyer peppas. It was observed that release was governed by the diffusion process. On basis of different properties MTP1 batch was found to be optimum. Study concludes that by the means of patches Torasemide can be administered efficiently.

Keywords: Torasemide, transdermal patches, HPMC, in-vitro release, stability studies, TDDS.

INTRODUCTION

Since previous years there are changes at major level in formulation technology. Innovations in drug delivery systems are not only related with novel pharmaceutical dosage forms but also resulted in development of new formulation for the treatment using existing drugs. These innovations in drug delivery system offer advantages, like improved patient compliance, maintaining steady state concentration levels of drug for prolonged period, reduced dosing frequency, and reduced side effects. TDDS manufacture has numerous benefits over other routes like oral delivery. It avoids limitations linked with g.i.t. absorption, enzyme effect, interaction with drug and food. This route is suitable when patient is suffering from vomiting and diarrhea. Reduced frequency of dose administration, and self-medication is possible. Since ancient time, skin is used by humans to apply different types of substances for the intention of therapeutic effect. In 20th century, skin is used for longer duration of delivery of different dosage forms. TDDS deliver drugs through skin. Transdermal Patch (TDP) is an adhesive system that is used after placing at skin surface. By the means of patches use of syringe as in parenteral routes can be avoided. That is associated with pain and thus not comfortable for patient specially children. TDP were first developed in the 1970s, and got approval through FDA in 1979. Initially these were limited for motion sickness having scopolamine. Later on TDP are continuously used for different purposes.

Based on the amount of drug, patches are used over the skin for 1 to 7 days. In general drug is kept in large dose inside the patch, to place over the skin for a longer time. By the means of diffusion process, the drug goes directly to the blood via the skin. Drug continuously diffuses to the skin as there is large concentration is present in patch. TDP contain membrane that controls the release of drug. Torasemide is a loop diuretic; it comes under category of sulfonyl urea. It is prescribed in the treatment of edema that is related with renal disease, CHF, or hepatic disease. It is also recommended for the hypertension treatment. Whenever it is used by oral route, it is associated with many side effects like vomiting, nausea, anorexia, and increased appetite. Since this drug is used for the long term duration, so patient compliance is very necessary aspect prior to use of this drug. Furthermore Torasemide is having short half life about 3.5 hr, so that there is need of frequent drug administration to maintain the therapeutic level. Matrix types of TDP are having advantages over others like easy to prepare without use of any sophisticated instrument and difficult procedure. Due to all these issues related with
Torasemide, it is a suitable candidate to prepare TDP to get controlled release and to avoid side effects and frequent administration.

**MATERIALS AND METHODS**

Torasemide was obtained as gift sample from Schwitz Biotech, Memnagar, Ahmedabad, Gujarat, PG (Polypropylene glycol), Glycerine, PVP K30 were obtained from CDH, Delhi. Chitosan was obtained from Central Institute of Fisheries, Cochin as gift sample. HPMC K100 (gms) from Cipla, Maharashtra and Ethyl cellulose from Asia private Ltd.Goa were obtained. All other ingredients were of analytical grade.

**Formulation development:**

Torasemide was mixed with solvent plasticizer, penetrations enhancer and polymers according the mentioned ratio. The whole mixture was transferred to a petri dish having area of 55 cm². In oven petri dishes, placed for 10 hrs with 40 °C temperature. In order to facilitate evaporation of the solvent, a funnel in inverted form placed over the solution. The prepared film was retrieved by the means of a blade and neutralized by NaOH (2 %). After it patches were stored in a desiccators for further use. Total of 12 formulations of TDP were prepared.

**Evaluation of TDP**

**Physical Properties**

1. **Thickness**

Screw gauge was use for the measurement of the thickness of matrix patches.

2. **Weight Uniformity**

Five matrix patches having area of 2.009 cm² were selected and weighed. Average wt was calculated.

3. **Content Uniformity**

Matrix patches having area of 2.009 cm², dissolved in 10 ml buffer. Later on % drug estimated through UV spectrophotometer at 232 nm and by using prepared standard curve of the Torasemide.

4. **Folding Endurance**

Matrix patches were folded many times at fixed position until their breakage. This test is for the estimation of elasticity of patches.

5. **% ML ( % Moisture Loss)**

Patches placed in a desiccators, having anhyd. CaCl₂ with 80-90%RH. Samples were taken from the desiccators after three days and weighed for the estimation of change in wt. Following equation was used to find % ML.

\[
\% \text{ ML} = \frac{\text{W}_i - \text{W}_f}{\text{W}_i} \times 100
\]

Where, \(\text{W}_i=\text{Weight Initial}, \text{W}_f=\text{Weight Final}\)

6. **% MC ( Moisture Content)**

At room temperature, patches placed in desiccators, having silica. Patches were taken from desiccators, with 80-90%RH and weighed continuously until a constant wt is shown by the patches. Following equation was used to find % MC.

\[
\% \text{ Moisture content} = \frac{\text{W}_i - \text{W}_f}{\text{W}_i} \times 100
\]

7. **% MA (Moisture Absorption)**

Patches placed in a desiccators, with 100 ml, AlCl₃ (79.5% RH). Samples were taken from the desiccators after three days and weighed for the estimation of change in wt. Following equation was used to find % MA.

\[
\% \text{ Moisture absorption} = \frac{\text{W}_f - \text{W}_i}{\text{W}_i} \times 100
\]

Where, \(\text{W}_i=\text{Weight Initial}, \text{W}_f=\text{Weight Final}\)

8. **WVTR (Water vap. transmission rate)**

Same size Vials were used as the cells, cleaned, and dried. CaCl₂ (1.0 gm) added to cells, patches having area 2.076 cm² were placed at the brim. After weighing cells were placed in a desiccator having KCl with humidity 80-90%. Cells were withdrawn and weighed daily for 7 days. WVTR was calculated using below equation.

\[
\text{WVTR} = \frac{\text{W}_f - \text{W}_i}{\text{T} \times \text{A}} \times 100
\]

Where, \(\text{W}_i=\text{Weight Initial}, \text{W}_f=\text{Weight Final}, \text{T}=\text{Time}, \text{A}=\text{Area}\)

9. **Flatness**

Matrix patches of length of 1.5cm were cutted from the prepared film. After it, the differences in length due to flatness uniformity was estimated by the below formula:

\[
\text{Constriction} (\%) = \frac{\text{LF} - \text{LI}}{\text{LI}} \times 100
\]

Where, \(\text{LF}=\text{length final}, \text{LI}=\text{length initial}\)

Patches showing 0% constrictions were considered to possess 100% flatness.

10. **In-vitro release studies**

For this study, locally fabricated Franz cell was used. This cell consists of donor and receptor compartment. A sampling port is attached with the receptor compartment to collect sample for the analysis. Both compartments are attached with rubber bands. Receptor compartment was flushed with buffer of Ph 7.4, and rotated with magnetic bead. A patch was incorporated with aluminum foil. One ml sample was withdrawn periodically for 7 hrs and analyzed by UV spectrophotometer at 232nm. After each withdrawal of the sample, a fresh buffer was added to it as a replacement.

**Drug release kinetic data analysis:**

Release data was evaluated through PCP disso software for the kinetic models. Zero, first, Higuchi’s and Peppas’s model were studied.

12. **Stability study**

Based on different evaluation parameters matrix patches of Torasemide of two batches MTP1 and MTP5 were found to be optimum formulations. These two formulations were subjected to accelerated study for the three months at different temperatures. The formulations of two batches MTP1 and MTP5 were air tight packed and kept for three months on 40°C (75% RH). Samples evaluated through UV spectrophotometer at 232 nm for the absorbance. By the means of the calibration curve the amount of the Torasemide was estimated.
RESULTS

Figure 1: Torasemide FTIR

Figure 2: Torasemide +PVP K30+ Chitosan+ Ethyl cellulose+ HPMC FTIR

Table 1: Torasemide Matrix patches formulations composition

| Batch  | Torasemide (mg) | Polymer Ratio | Solvent (w/v) | Propylene glycol (Penetration enhancer) | Plasticizer                  |
|--------|-----------------|---------------|---------------|------------------------------------------|-----------------------------|
| MTP1   | 250             | Chitosan: PVP K30::20:80 | Acetic acid(1%) | 10% | Dibutylphthalate (30%) |
| MTP2   | 250             | Chitosan: PVP K30::40:60 | Acetic acid(1%) | - | Dibutylphthalate (30%) |
| MTP3   | 250             | Chitosan: PVP K30::60:40 | Acetic acid(1%) | - | Dibutylphthalate (30%) |
| MTP4   | 250             | Chitosan: PVP K30::80:20 | Acetic acid(1%) | - | Dibutylphthalate (30%) |
| MTP5   | 250             | Chitosan :EC:: 20:80 | Dichloromethane (2%) | 10% | Dibutylphthalate (30%) |
| MTP6   | 250             | Chitosan :EC:: 40:60 | Acetic acid(1%) | 10% | Dibutylphthalate (30%) |
| MTP7   | 250             | Chitosan :EC:: 60:40 | Acetic acid(1%) | - | Glycerine (20%) |
| MTP8   | 250             | Chitosan :EC:: 80:20 | Dichloromethane (2%) | - | Castor oil (20%) |
| MTP9   | 250             | HPMC:PVP K30::20:80 | Dichloromethane (2%) | - | Castor oil (20%) |
| MTP10  | 250             | HPMC:PVP K30::40:60 | Dichloromethane (2%) | - | Castor oil (20%) |
| MTP11  | 250             | HPMC:PVP K30::60:40 | Acetic acid(1%) | - | Castor oil (20%) |
| MTP12  | 250             | HPMC:PVP K30::80:20 | Acetic acid(1%) | - | Castor oil (20%) |
Table 2: Properties of Torasemide matrix patches

| Code   | Physical Appearance                      | Thickness (mm) ± SD | Mass Uniformity (mg) | % Drug Content | % Moisture Content |
|--------|------------------------------------------|---------------------|----------------------|----------------|-------------------|
| MTP1   | Smooth tough                             | 0.039 ± 0.41        | 44.5 ± 0.12          | 95.42± 0.12    | 2.65 ± 0.09       |
| MTP2   | Smooth tough                             | 0.037 ± 0.09        | 43.3 ± 0.08          | 96.42± 0.09    | 2.69 ± 0.16       |
| MTP3   | Smooth flexible but wrinkled             | 0.040 ± 0.21        | 42.7 ± 0.08          | 94.42± 0.09    | 2.59 ± 0.16       |
| MTP4   | Smooth tough                             | 0.038 ± 0.08        | 46.2 ± 0.11          | 95.41± 0.21    | 2.45 ± 0.13       |
| MTP5   | Smooth flexible but wrinkled             | 0.036 ± 0.19        | 45.7 ± 0.14          | 97.35± 0.32    | 2.55 ± 0.15       |
| MTP6   | Smooth flexible but wrinkled             | 0.040 ± 0.09        | 47.6 ± 0.09          | 97.62± 0.12    | 3.43 ± 0.64       |
| MTP7   | Smooth tough                             | 0.038 ± 0.18        | 44.4 ± 0.15          | 96.79± 0.12    | 3.24 ± 0.65       |
| MTP8   | Smooth flexible but wrinkled             | 0.041 ±0.31         | 45.1 ± 0.18          | 97.65± 0.12    | 3.45 ± 0.21       |
| MTP9   | Hard and tough                           | 0.051 ± 0.09        | 43.2 ± 0.23          | 96.31± 0.15    | 3.35 ± 0.24       |
| TP10   | Smooth tough                             | 0.037 ± 0.19        | 45.7 ± 0.11          | 97.31± 0.32    | 2.35 ± 0.16       |
| MTP11  | Smooth flexible but wrinkled             | 0.038 ± 0.09        | 46.6 ± 0.11          | 97.22± 0.09    | 3.43 ± 0.59       |
| MTP12  | Smooth flexible but wrinkled             | 0.041 ± 0.11        | 48.7 ± 0.09          | 98.45± 0.09    | 3.79 ± 0.08       |

Table 3: Characterization of Torasemide matrix patches

| Batch Code | % MA     | % ML     | WVTR (g/cm²/hrs) | Folding Endurance | Flatness |
|------------|----------|----------|------------------|-------------------|----------|
| MTP1       | 6.44 ± 0.07 | 2.88 ± 0.09 | 2.327 ± 0.11 | > 254 | 100% |
| MTP2       | 5.32 ± 0.09 | 3.45 ± 0.08 | 2.428 ± 0.13 | > 235 | 100% |
| MTP3       | 4.35 ± 0.09 | 2.82 ± 0.11 | 2.631 ± 0.14 | > 264 | 100% |
| MTP4       | 5.48 ± 0.11 | 3.23 ± 0.12 | 2.747 ± 0.09 | > 278 | 100% |
| MTP5       | 6.78 ± 0.09 | 3.43 ± 0.14 | 2.832 ± 0.08 | > 265 | 100% |
| MTP6       | 7.10 ± 0.21 | 3.75 ± 0.09 | 1.458 ± 0.14 | > 267 | 100% |
| MTP7       | 6.23 ± 0.32 | 3.54 ± 0.08 | 1.871 ± 0.21 | > 282 | 100% |
| MTP8       | 8.13 ± 0.41 | 3.63 ± 0.14 | 1.562 ± 0.09 | > 257 | 100% |
| MTP9       | 8.10 ± 0.09 | 3.55 ± 0.21 | 1.358 ± 0.21 | > 260 | 100% |
| TP10       | 7.78 ± 0.11 | 3.53 ± 0.12 | 1.832 ± 0.11 | > 257 | 100% |
| MTP11      | 5.35 ± 0.32 | 3.82 ± 0.18 | 2.531 ± 0.16 | > 253 | 100% |
| MTP12      | 6.32 ± 0.29 | 3.55 ± 0.11 | 1.428 ± 0.14 | > 247 | 100% |

Figure 3: In vitro study of patches (MTP1 to MTP4)
Table 4: Different release models for Torasemide transdermal patches

| Batch | Kinetic model               | Parameters               |
|-------|----------------------------|--------------------------|
| MTP1  | Peppas and Korsmeyer       | R = 0.972, K1 = 7.642, n = 0.732 |
| MTP2  | Peppas and Korsmeyer       | R = 0.971, K1 = 7.442, n = 0.762 |
| MTP3  | First order                | R = 0.962, K1 = 5.61, n = 0.760 |
| MTP4  | Peppas and Korsmeyer       | R = 0.954, K1 = -0.070    |
| MTP5  | Peppas and Korsmeyer       | R = 0.974, K1 = 5.2154, n = 0.864 |
| MTP6  | Peppas and Korsmeyer       | R = 0.983, K1 = 6.712, n = 0.782 |
| MTP7  | Peppas and Korsmeyer       | R = 0.955, K1 = 4.284, n = 0.760 |
| MTP8  | Peppas and Korsmeyer       | R = 0.963, K1 = 8.243, n = 0.718 |
| MTP9  | Peppas and Korsmeyer       | R = 0.975, K1 = -0.034    |
| MTP10 | First order                | R = 0.984, K1 = 3.157, n = 0.864 |
| MTP11 | Peppas and Korsmeyer       | R = 0.975, K1 = 5.846, n = 0.863 |
| MTP12 | Peppas and Korsmeyer       | R = 0.969, K1 = 7.451, n = 0.745 |

**Figure 4:** *In vitro* study of patches (MTP5 to MTP8)

**Figure 5:** *In vitro* study of patches (MTP9 to MTP12)
DISCUSSION
Torasemide was Schwitz Biotech, Memnagar, Ahmedabad, Gujarat as a Gift sample. The drug was authenticated by different test i.e. solubility, melting point, test according to Indian Pharmacopoeia and analytical methodology was performed on sample to justify the authenticity of sample. The m.p. detected was in the range of 161-165°C, that is matching as mentioned in IP. This justifies the authenticity of given sample of Torasemide. Torasemide sample was soluble in H2O, but sparingly in alcohol. This justifies the authenticity of given sample of Torasemide.

Analytical methodology- Given Torasemide sample has shown maximum absorption (λmax) at 232nm. FTIR spectroscopy was used to detect any kind of interaction between Torasemide and used polymers i.e. HPMC, EC, PPV K30. No change in peak was found, that indicate compatibility between them.

Development and evaluation of formulations-
Twelve Torasemide matrix patches were developed using polymers in different ratio and plasticizer and penetration enhancer.

Thickness, weight and % content:
Measured thickness of twelve patches was found to be in between0.037 ± 0.19-0.051 ± 0.09 mm. Average thicknesses within a batch was uniform, with a little variation. This difference is because of viscosity difference of polymer solution and also due to absence of temperature control that affect solvent evaporation. Measured weight of twelve patches was found to be in 42.7 ± 0.08 to 48.7 ± 0.09mg. Measured % drug content found to be 94.42±0.09 to 98.45±0.09.

% ML, % MC, % MA, and WVTR
% MA was found to be in the range of 4.355 ± 0.09 to 8.132 ± 0.41, maximum was observed in MTP8 and minimum in MTP3. % MC was found to be in the range of 2.35 ± 0.16 to 3.79 ± 0.08, maximum was observed in MTP12 and minimum in MTP9. % ML was found to be in the range of 2.881 ± 0.09 to 3.824 ± 0.18 maximum was observed in MTP11 and and minimum in MTP1. WVTR was found is maximum in batch code MTP5 i.e. 2.832X10^-4 ± 0.08 and minimum in formulations of batch code MTP9 i.e. 1.358X10^-4 ± 0.21.

Folding endurance-
It was found maximum in formulation MTP7 (>282) and least in MTP2 (>235). This indicates that due to use of plasticizer, all twelve patches were having sufficient elasticity.

In-vitro release
Release profile of twelve batches of Torasemide was done by the means of Franz cell for 7 hrs. Largest in batch code MTP6
Slow dissolution in different models i.e. first, and...

The profile of...

Torasemide. An update of its...

Twelve Torasemide matrix patches were developed using different polymers in different ratio and plasticizer and penetration enhancer. All transdermal patches were transparent and free from any particle. Release of Torasemide was governed by the diffusion process. In-vitro release data were plotted in 2 different models i.e. first, and Korsemeyer Peppas. It was observed that release was governed by the diffusion process.

Stability study:

12 weeks study indicates that patch formulation of MTP1 and MTP5 are capable to be stable at 45°C as well as at refrigeration temperature. Therefore, the formulations may be kept at room temperature without affecting the properties.

CONCLUSION

Twelve Torasemide matrix patches were developed using different polymers in different ratio and plasticizer and penetration enhancer. All transdermal patches were transparent and free from any particle. Release profile of twelve batches of Torasemide was done by the means of Franz cell for 7 hrs. Maximum release was shown by MTP1 (71.28±0.19) and least in formulations of batch code MTP7 (24.47±0.04). In-vitro release data were plotted in 2 different models i.e. first, and Korsemeyer Peppas. It was observed that release was governed by the diffusion process.

On basis of different properties MTP1 batch was found to be optimum.

REFERENCES

1. Ashu Mittal, Udaivir Singh, Asgar Ali. Formulation and evaluation of monolithic matrix polymer films for transdermal delivery of nitrendipine. Acta Pharm. 2009; 59:383–393.

2. Kusum DV, SaiSowm S, Maria GR, Deepthi PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev. Ind. Pharm. 2003; 29:495–503.

3. Limpongse E, Umprayan K. Preparation and evaluation of diltiazem hydrochloride diffusion controlled transdermal delivery system. AAPS PharmSciTech. 2008; 9(2):464-70.

4. Sakellarious P, Rowe RC, White ET. An evaluation of the interaction and plasticizing efficacy of the polyethylene glycols in cellulose and hydroxypropyl methylcellulose films using the torsional braid pendulum. Int J Pharm.1986; 31:55–64.

5. Costa P, Ferreria DC, Morgado R, Sousa Lobo JM. Design and evaluation of a lornipam transdermal delivery system, Drug Dev Ind Pharm. 1997; 23:939-944.

6. Dimas DA, Dalles PP, Reklas DD, Choulis NH. Effect of several factors on the mechanical properties of pressure sensitive adhesives used in transdermal therapeutic systems, AAPS PharmSciTech. 2000; 1:16.

7. Gabiga H, Cal K, Janidi S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system, Int J Pharm. 2000; 199: 1-6.

8. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclo-dextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018; 536(1):95-107.

9. Elsadeh EH, Dawaba HM, Ibrahim EA, Afoua MI. Investigation of prinosiosomes gel as a promising carrier for transdermal delivery of Glimepiride. Universal Journal of Pharmaceutical Research 2016; 1(2):1-10.

10. Izumoto T, Aioi A, Uenooyama S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch and physicochemical properties, Chem Pharm Bull (Tokyo) 1992; 40:456-458.

11. Gaur RP, Mehta S, Pruthi S and Dave K: Transdermal delivery system: A review. Asian journal of Pharmaceutical and Clinical Research 2009; 2(1):14-20.

12. Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG. "Torasemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis". J Cardiovasc Med (Hagerstown). 2019; 20(6):379–386.

13. Wargo KA, Banta WM (November 2009). "A comprehensive review of the loop diuretics: should furosemide be first line?". Ann Pharmacother. 43(11):1836–47.

14. Dunn GJ, Fittigon A, Brogden RN. "Torasemide. An update of its pharmacological properties and therapeutic efficacy". Drugs. 1995; 49(1):121–42.

15. Francis DJE. Development and evaluation of matrix type transdermal patches of piglitazine hydrochloride. Universal Journal of Pharmaceutical Research 2016; 1(1):17-20.

16. Chauhan N, Kumar K, Pun N. An updated review on transfersomes: a novel vesicular system for transdermal drug delivery. Universal Journal of Pharmaceutical Research 2017; 2(4):42-45.

17. Arunachalam A, Karthikeyan, Vinay Kumar D, Prathap M, Sethuraman S, Ashutosh Kumar S and Manidipa S: Transdermal Drug Delivery System: A review. Current Pharma Research 2010; 1(1):70-81.

18. Ammaiaikut C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use, Int. J Pharm. 2005; 289:167–178.

19. Verma PPR, Iyer SS. Transdermal delivery of propranolol using mixed grades of Eudragit: design and in-vitro and in vivo evaluation. Drug Dev. Ind. Pharm. 2000; 26:471–476.

20. Chrioma ED. Formulation and evaluation of etodolac niosomes by modified ether injection technique. Universal Journal of Pharmaceutical Research 2016; 1(1):1-4.

21. Durrviya Hashmat, Muhammad Harris Shoaib1*, Fatima Ramzan Ali, Fahad Siddiqui. Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers. PLOS ONE February 27, 2020

22. B Raja Narender. Formulation and Evaluation of Physostigmine-Transdermal Patch. World Journal of Current Med and Pharm Research, Vol-II, Iss-II, 125-132.

23. Umar S, Onyekachi LK. Development and evaluation of transdermal gel of Lornoxicam. Universal Journal of Pharmaceutical Research 2017; 2(1):15–18.

24. Baghel S, Naved T, Parvez N. Formulation and development of transdermal drug delivery system of ethinylestradiol and testosterone: in vitro evaluation. Int J App Pharm, 2019; 11(1):55-60.

25. Ibrah Jabiri Muhammad Harris Shoaib · Rabia Ismail Yousuf1 · Fatima Ramzan Ali. Effect of permeation enhancers on in vitro release and transdermal delivery of lamotrigine from Eudragit® RS100 polymer matrix type drug in adhesive patches. Progress in Biomaterials 2019; 8:91–100.

26. Kharia A, Gholtra R, Singhai AK. Formulation and evaluation of transdermal patch for treatment of inflammation. International Journal of Pharmaceutical Sciences and Research. 2019; Vol. 10(5):2375-2384.

27. Fatima AA, Chukwuka UK. Development and in-vitro evaluation of matrix-type transdermal patches of Iosartan potassium. Universal Journal of Pharmaceutical Research 2017; 2(2):16-20.